1. Home
  2. FSP vs LITS Comparison

FSP vs LITS Comparison

Compare FSP & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

HOLD

Current Price

$0.38

Market Cap

33.3M

Sector

Real Estate

ML Signal

HOLD

LITS

Lite Strategy Inc.

SELL

Current Price

$0.81

Market Cap

36.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FSP
LITS
Founded
1981
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.3M
36.3M
IPO Year
2001
2003

Fundamental Metrics

Financial Performance
Metric
FSP
LITS
Price
$0.38
$0.81
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 591.3K
257.2K
Earning Date
10-27-2026
11-10-2026
Dividend Yield
★ 2.66%
N/A
EPS Growth
★ 15.69
13.81
EPS
N/A
★ 0.48
Revenue
★ $107,162,000.00
N/A
Revenue This Year
$16.75
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$1.75
Revenue Growth
★ N/A
N/A
52 Week Low
$0.30
$0.69
52 Week High
$1.05
$1.99

Technical Indicators

Market Signals
Indicator
FSP
LITS
Relative Strength Index (RSI) 44.11 36.17
Support Level $0.31 $0.69
Resistance Level $0.40 $1.24
Average True Range (ATR) 0.03 0.09
MACD -0.01 -0.01
Stochastic Oscillator 9.57 22.59

Price Performance

Historical Comparison
FSP
LITS

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.

Share on Social Networks: